title: Incidence of cholinesterase inhibitor therapy initiation among hospitalized patients.
abstract: BACKGROUND
  Initiation of cholinesterase inhibitor (ChEI) therapy for delirium during hospitalization is ineffective and may be associated with increased morbidity and mortality.
  
  
  OBJECTIVE
  To describe the incidence of initiating ChEI therapy during hospitalization.
  
  
  METHODS
  A retrospective cross-sectional study.
  
  
  METHODS
  A tertiary-care academic medical center.
  
  
  METHODS
  Inpatient admissions from September 2010 through March 2011 with ChEI administration.
  
  
  METHODS
  None.
  
  
  METHODS
  Incidence of ChEI exposure, initiation of ChEI therapy, initiation of antipsychotics and benzodiazepines, infection, in-hospital mortality, and hospital length of stay.
  
  
  RESULTS
  The incidence of adult admissions with ChEI exposure and ChEI initiation was 23.2 (95% confidence interval: 21.2-25.4) and 2 (95% confidence interval 1.5-2.8) per 1000 admissions, respectively. Of 476 admissions receiving ChEI, 9% (n = 42) initiated therapy during the hospital stay and 91% (n = 434) continued on previously started therapy. Patients initiated on ChEI therapy frequently had infection (20 of 42) and were commonly initiated on antipsychotics (14 of 42) and benzodiazepines (13 of 42). Patients were hospitalized for a median of 2 days (interquartile range, 1-4) before initiation of ChEI and were exposed to therapy for a median of 3 days (interquartile range, 2-6). Of the 41 patients discharged from the hospital, 90% (n = 37) had orders to continue the ChEI postdischarge.
  
  
  CONCLUSIONS
  Despite a lack of evidence to support the practice, 9% of patients who received ChEI therapy were initiated during the inpatient setting. These patients were not routinely screened for delirium and frequently received treatments associated with delirium.
authors.affiliation: Texas Southern University, Houston, TX 77021, USA. swan.joshua@gmail.com
authors.forename: Joshua T
authors.initials: JT
authors.lastname: Swan
authors.forename: Kamal C
authors.initials: KC
authors.lastname: Wagle
authors.forename: Nathaniel
authors.initials: N
authors.lastname: Thompson-Moore
authors.forename: George E
authors.initials: GE
authors.lastname: Taffet
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002800:Cholinesterase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D003693:Delirium / Q000188:drug therapy* / Q000201:enzymology / Q000453:epidemiology*; D005260:Female; D017052:Hospital Mortality / Q000639:trends*; D006760:Hospitalization / Q000639:trends*; D006801:Humans; D015994:Incidence; D008297:Male; D012189:Retrospective Studies
chemical_list: D002800:Cholinesterase Inhibitors